{"id":"rituximab-methotrexate-temozolomide","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Infusion-related reactions"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Anemia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Neutropenia"},{"rate":"5-10%","effect":"Leukopenia"},{"rate":"5-10%","effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Rituximab works by binding to the CD20 antigen on the surface of B cells, leading to their depletion. Methotrexate inhibits dihydrofolate reductase, which is necessary for DNA synthesis and cell division. Temozolomide alkylates DNA, causing cross-links that prevent DNA replication and transcription.","oneSentence":"Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells, while Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, and Temozolomide is an alkylating agent that cross-links DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:30.016Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-Hodgkin's lymphoma"},{"name":"Rheumatoid arthritis"},{"name":"Glioblastoma multiforme"}]},"trialDetails":[{"nctId":"NCT07015242","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-11-06","conditions":"Lymphoma","enrollment":65},{"nctId":"NCT02203526","phase":"PHASE1","title":"Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-08-14","conditions":"Primary Central Nervous System Lymphoma","enrollment":93},{"nctId":"NCT07350850","phase":"PHASE2","title":"A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-25","conditions":"PCNSL, Primary Central Nervous System Lymphoma","enrollment":110},{"nctId":"NCT06475235","phase":"PHASE1","title":"Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-10-18","conditions":"Lymphoma, Primary Central Nervous System Lymphoma","enrollment":15},{"nctId":"NCT03964090","phase":"PHASE2","title":"Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-27","conditions":"Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma","enrollment":48},{"nctId":"NCT04947319","phase":"PHASE2","title":"Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2021-12-29","conditions":"Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma","enrollment":119},{"nctId":"NCT04737889","phase":"PHASE2","title":"Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2021-01-13","conditions":"Primary Central Nervous System Lymphoma","enrollment":30},{"nctId":"NCT06832267","phase":"NA","title":"Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-02-14","conditions":"Primary Central Nervous System Lymphoma","enrollment":44},{"nctId":"NCT03495960","phase":"PHASE2","title":"Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2019-06-15","conditions":"Primary Central Nervous System Lymphoma","enrollment":72},{"nctId":"NCT06445257","phase":"NA","title":"A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL","status":"RECRUITING","sponsor":"Huai'an First People's Hospital","startDate":"2023-09-15","conditions":"Primary Central Nervous System Lymphoma","enrollment":30},{"nctId":"NCT04656431","phase":"PHASE1","title":"Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma","status":"UNKNOWN","sponsor":"James Rubenstein","startDate":"2021-06-29","conditions":"Primary CNS Lymphoma","enrollment":25},{"nctId":"NCT05896007","phase":"PHASE2","title":"Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2023-07-13","conditions":"PCNSL","enrollment":29},{"nctId":"NCT02313389","phase":"PHASE3","title":"Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-09","conditions":"Primary Central Nervous System Lymphoma","enrollment":428},{"nctId":"NCT00068250","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2003-07","conditions":"Brain and Central Nervous System Tumors, Lymphoma","enrollment":60},{"nctId":"NCT00098774","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2004-10","conditions":"Lymphoma","enrollment":47},{"nctId":"NCT00416819","phase":"NA","title":"Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2003-09","conditions":"Brain and Central Nervous System Tumors, Lymphoma","enrollment":10},{"nctId":"NCT02399189","phase":"PHASE2","title":"MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma","status":"UNKNOWN","sponsor":"Jun Zhu","startDate":"2014-05","conditions":"Primary Central Nervous System Lymphoma","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Rituximab, Methotrexate, Temozolomide","genericName":"Rituximab, Methotrexate, Temozolomide","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells, while Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, and Temozolomide is an alkylating agent that cross-links DNA. Used for Non-Hodgkin's lymphoma, Rheumatoid arthritis, Glioblastoma multiforme.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}